The combination of crizotinib with the ERBBi afatinib demonstrated synergistic cytotoxic effects, significantly reducing 2D and 3D invasion, migration and colony formation independent of BRAF/NRAS mutation status, and resulting in decreased tumour volume in vivo (Das et al., 2019; Das et al., 2020). Here, NRAS is linked to neoplasm.